Evidence map›Paper›PMID 35490737›Full record

ArticleThe Journal of infection2022

Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.

Daniel Jiménez, Javier Martínez-Sanz, Talía Sainz, Cristina Calvo, Ana Méndez-Echevarría, Elena Moreno, Daniel Blázquez-Gamero, Pilar Vizcarra, Mario Rodríguez, Robert Jenkins and 6 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Daniel JiménezDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain.
Javier Martínez-SanzDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain. Electronic address: javier.martinez.sanz@salud.madrid.org.
Talía SainzDepartment of Pediatrics, Tropical and Infectious Diseases, Hospital La Paz, and La PazResearch Institute (IdiPAZ), Traslational Research Network of Pediatric Infectious Diseases (RITIP), and CIBERINFEC, Madrid, Spain.
Cristina CalvoDepartment of Pediatrics, Tropical and Infectious Diseases, Hospital La Paz, and La PazResearch Institute (IdiPAZ), Traslational Research Network of Pediatric Infectious Diseases (RITIP), and CIBERINFEC, Madrid, Spain.
Ana Méndez-EchevarríaDepartment of Pediatrics, Tropical and Infectious Diseases, Hospital La Paz, and La PazResearch Institute (IdiPAZ), Traslational Research Network of Pediatric Infectious Diseases (RITIP), and CIBERINFEC, Madrid, Spain.
Elena MorenoDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain.
Daniel Blázquez-GameroPediatric Infectious Diseases Unit. Hospital Universitario 12 de Octubre. Universidad Complutense, Instituto de Investigación Hospital 12 de Octubre (imas12), Traslational Research Network of Pediatric Infectious Diseases (RITIP), Madrid, Spain.
Pilar VizcarraDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain.
Mario RodríguezDepartment of Microbiology, Facultad de Medicina, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, Spain.
Robert JenkinsReactomix S.L., Granada 18003, Spain.
Matilde Sánchez-CondeDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain.
Raquel RonDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain.
Francesca NormanDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain.
Santiago MorenoDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain.
Manuel FerrerInstitute of Catalysis, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Sergio Serrano-VillarDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá and CIBERINFEC, Madrid, Spain. Electronic address: sergio.serrano@salud.madrid.org.
Universidad de Alcalá · ESHospital La Paz Institute for Health Research · ESHospital Universitario Ramón y Cajal · ESConsejo Superior de Investigaciones Científicas · ESResearch Institute Hospital 12 de Octubre · ESTiGenix (Spain) · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVariations in the ACE2 activity in saliva could explain the striking differences of susceptibility to infection and risk of severe disease.

methodsWe analyze the activity of ACE2 in saliva in different population groups across a wide age range and disease status during April to June 2020, before SARS-CoV-2 vaccine implementation, and we establish differences between infected people and participants considered resistant (highly exposed healthcare workers and children who cohabited with parents with COVID-19 without isolation and remain IgG negative).

resultsWe included 74 adults, of which 47 (64%) were susceptible and 27 (36%) were resistant, and 79 children, of which 41 (52%) were susceptible and 38 (48%) were resistant. Resistant adults have significantly lower ACE2 activity in saliva than susceptible adults and non-significant higher values than susceptible and resistant children. ACE2 activity is similar in the susceptible and resistant pediatric population (p = 0.527). In contrast, we observe an increase in activity as the disease's severity increases among the adult population (mild disease vs. severe disease, 39 vs. 105 FU, p = 0.039; severe disease vs. resistant, 105 vs. 31 FU, p < 0.001).

conclusionsusing an enzymatic test, we show that ACE2 activity in saliva correlates with the susceptibility to SARS-Cov-2 infection and disease severity. Children and adults with low-susceptibility to SARS-Cov-2 infection showed the lowest ACE2 activity. These findings could inform future strategies to identify at-risk individuals.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19SARS-CoV-2AdultChildCOVID-19 VaccinesHumansSalivaACE2 protein, humanAngiotensin-Converting Enzyme 2COVID-19 VaccinesACE2SalivaSARS-CoV-2SeveritySusceptibility

Identifiers

PMID35490737
PMCPMC9050198
OpenAlexW4225293137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.